Eli Lilly
Eli Lilly was founded in 1876 and is headquartered in Indianapolis, US
Report incorrect company information
Key People/Management at Eli Lilly
David A. Ricks
Chairman and Chief Executive Officer
Melissa Stapleton Barnes
Senior Vice President, Enterprise Risk Management, and Chief Ethics and Compliance Officer
Enrique A. Conterno
Senior Vice President and President, Lilly Diabetes and Lilly USA
Stephen F. Fry
Senior Vice President, Human Resources and Diversity
Michael J. Harrington
Senior Vice President and General Counsel
Susan Mahony
Senior Vice President and President, Lilly Oncology
Report incorrect company information
Eli Lilly Office Locations
Eli Lilly has offices in Indianapolis, Chuo Ward, Wien, Melrose Park and in 141 other locations
Indianapolis, US (HQ)
Lilly Corporate Center
Melrose Park, AU
112 Wharf Rd
Wien, AT
8-10 Kölblgasse
Toronto, CA
3650 Danforth Ave
Chuo Ward, JP
Sannomiya Plaza Building 7-1-5 Isogami-dori Chuo-ku, Kobe
Windlesham, GB
Erl Wood Manor Sunninghill Road
Report incorrect company information
Eli Lilly Financials and Metrics
Eli Lilly Revenue
Eli Lilly's revenue was reported to be $21.22 b in FY, 2016 which is a 6.3% increase from the previous period.
| USD | |
|---|---|
Market capitalization (16-Aug-2018) | 112.1 b |
Closing stock price (16-Aug-2018) | 104.4 |
Eli Lilly's current market capitalization is $112.1 b.
Annual
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 4.7 b | 2.4 b | 2.4 b | 2.7 b |
Cash From Operating Activities | 5.7 b | 4.4 b | 2.8 b | 4.9 b |
Purchases of PP&E | (1 b) | (1.2 b) | (1.1 b) | (1 b) |
Cash From Investing Activities | (2.1 b) | (3.9 b) | 26.8 m | (3.1 b) |
Eli Lilly Operating Metrics
| FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | |
|---|---|---|---|---|
Phase III Trials Products | 8 | 7 | 17 | 19 |
Projects in R&D Pipeline | 57 | 57 | 65 | 66 |
Eli Lilly Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| AurKa Pharma | May 15, 2018 | $575 m |
| ARMO BioSciences Inc | May 11, 2018 | $1.60 b |
| CoLucid Pharmaceuticals | January 18, 2017 | $960 m |
| Novartis Animal Health | April 22, 2014 | $5.40 b |
| Avid Radiopharmaceuticals | November 08, 2010 | $800 m |
| Alnara Pharmaceuticals | July 02, 2010 | $280 m |
| Imclone Systems | October 06, 2008 | $6.50 b |
Report incorrect company information
Eli Lilly Online and Social Media Presence
175.33k Facebook likes
Eli Lilly has 175.33k Facebook Likes. The number of likes has increased 8.1% month over month and increased 15.1% quarter over quarter
Report incorrect company information
Eli Lilly News and Updates
August 20, 2018
US Rheumatologists' Early Views on Eli Lilly's Olumiant for the Treatment of Rheumatoid Arthritis Show Uphill Battle, While Pfizer's Xeljanz Holds Ground as the Preferred JAK Inhibitor
EXTON, Pa., Aug. 20, 2018 /PRNewswire/ -- Spherix Global Insights' third quarter update of RealTime Dynamix™: Rheumatoid Arthritis (US) captured initial insights on Eli Lilly's long-awaited launch of Olumiant (baricitinib). While three-quarters of rheumatologists (n=99) are aware of the...
July 24, 2018
Eli Lilly to take animal health unit public, profit beats estimates
Eli Lilly and Co announced on Tuesday it would take its Elanco animal health business public and posted better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.
July 24, 2018
Eli Lilly to spin off animal health unit, quarterly profit beats estimates
Eli Lilly and Co announced on Tuesday it would spin off its Elanco animal health business and posted better-than-expected quarterly profit, helped by demand for its diabetes drugs Trulicity and Humalog.
July 24, 2018
Eli Lilly spins off animal health unit, second quarter beats
Eli Lilly and Co on Tuesday said it would spin off its Elanco animal health business into a publicly-traded company and posted better-than-expected quarterly profit helped by demand for its diabetes drugs Trulicity and Humalog.
July 24, 2018
Eli Lilly posts quarterly loss
Eli Lilly and Co posted a second-quarter loss on Tuesday, hurt by acquisition-related charges to the tune of $1.62 billion.
Report incorrect company information
Eli Lilly Company Life and Culture
Report incorrect company information